

Data Sheet

| | |
|----------------------------------|---|
| NAME : | vT198 |
| REPOSITORY REFERENCE : | ARP2039 |
| PROVIDED: | 250 µL ell free virus, 4.69 X 10 ⁹ pfu/ml. |
| DESCRIPTION: | The HIV-1 _{92ug037.1} env gene was modified to introduce silent mutations to remove two internal T ₅ NT sequences encoding vaccinia virus early transcription termination sequences, and to delete 14 aa of the signal peptide sequence. A plasmid containing the env gene under the control of the vaccinia synthetic early/late (sE/L) promoter, the gag-pol genes under control of the vaccinia 40K (H6) promoter, and the K1L host range gene was transfected into RK ₁₃ cells infected with vAbT33,a K1L-,M2L-,LacZ |
| SPECIAL CHARACTERISTICS : | Cells infected with vT198 express HIV-1 _{92UG037.1} (subtype A). env-,gag-, and pol-encoded polypeptides. |
| STERILITY: | Negative for bacteria, fungi, and mycoplasma. |
| STORAGE : | -70°C |
| SOURCE : | Therion Biologics Corporation, in collaboration with Dr. Feng Gao and Dr. Beatrice Hahn. Viruses expanded by Quality Biological, Inc. (courtesy of NIH AIDS Research and reference Reagent Programme.) |

NOTE:

Requests from commercial institutions should be directed to Dr. Gail Mazzara, Vice President, R & D, Therion Biologics Corp., 76 Rogers St., Cambridge, MA 02142

ACKNOWLEDGEMENTS :

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)